AbbVie submits marketing authorization application for risankizumab 150mg for treatment of psoriatic arthritis to European Medicines Agency

The submissions were supported by two pivotal phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2, reporting significant improvements in disease activity (ACR20 response), skin clearance (PASI 90) and physical function (HAQ-DI) at week 24 versus placebo.

Source:

Biospace Inc.